Eton Pharmaceuticals Announces Appointment of Ingrid Hoos as Senior Vice President of Scientific Affairs

Rhea-AI Summary

Eton Pharmaceuticals (Nasdaq: ETON) has appointed Ingrid Hoos as the new Senior Vice President of Scientific Affairs. Hoos, previously Vice President of Regulatory Affairs at Horizon Therapeutics, brings substantial experience, having overseen the growth of Horizon's FDA-approved products from one to ten during her tenure. Eton CEO Sean Brynjelsen expressed confidence in Hoos's track record with complex product approvals and her potential to contribute to the company’s growth. Eton's focus remains on developing pediatric rare disease products, including its lead product, Alkindi® Sprinkle, currently under FDA review.

Positive

• Ingrid Hoos brings significant regulatory experience, enhancing Eton's leadership team.
• Hoos's previous success with FDA approvals could accelerate Eton's product development and pipeline.
• The appointment signals Eton's commitment to advancing its pediatric rare disease products.

Negative

• There may be concerns regarding the continuity of leadership as the company transitions.
• Ingrid Hoos's prior role suggests a shift in the regulatory strategy that could pose risks during implementation.

DEER PARK, Ill., Aug. 31, 2020 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, today announced that it has appointed Ingrid Hoos as the company’s new Senior Vice President of Scientific Affairs. In the new role, Ms. Hoos will support the company’s regulatory, product development, and quality activities. 

Ms. Hoos joins Eton after spending nine years as Vice President of Regulatory Affairs at Horizon Therapeutics. At Horizon, Ms. Hoos was responsible for the company’s regulatory strategy and regulatory operations. During her tenure, Horizon’s portfolio grew from one FDA-approved product to ten FDA-approved products. Prior to Horizon Therapeutics, Ingrid held leadership roles in regulatory, quality, and product development at Baxter Healthcare, Takeda Pharmaceuticals, and G.D. Searle (now Pfizer).

“We are pleased to have Ingrid joining the team. Ingrid has an impressive track record of successfully working with the FDA to gain approval of complex products, and she has first-hand experience growing an industry leading pharmaceutical company,” said Sean Brynjelsen, CEO of Eton Pharmaceuticals.

Ingrid Hoos added, “I am excited to join Eton at such a critical point in its history and to have the opportunity to be part of another young and rapidly growing pharmaceutical company. I look forward to immediately working towards gaining FDA-approval of Eton’s pipeline products.”

About Eton Pharmaceuticals

Eton Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing, acquiring, and commercializing pediatric rare disease products. The company’s first commercial product, Biorphen, is the only FDA approved ready-to-use formulation of phenylephrine injection and was launched in December 2019. The company’s lead pediatric product is the orphan drug Alkindi^® Sprinkle, which is currently under review with the FDA. The company has an additional seven products under development, including five that are under review with the FDA.

Company Contact:

David Krempa
dkrempa@etonpharma.com
612-387-3740

FAQ

Who is Ingrid Hoos and what is her role at Eton Pharmaceuticals?

Ingrid Hoos is the new Senior Vice President of Scientific Affairs at Eton Pharmaceuticals, where she will support regulatory, product development, and quality activities.

What experience does Ingrid Hoos have in the pharmaceutical industry?

Ingrid Hoos has nine years of experience as Vice President of Regulatory Affairs at Horizon Therapeutics, where she helped increase FDA-approved products from one to ten.

Why is Eton Pharmaceuticals appointing a new Senior Vice President at this time?

The appointment comes at a critical point in Eton's growth as it aims to advance its product pipeline, including gaining FDA approval for its drugs.

How might Ingrid Hoos's appointment impact Eton Pharmaceuticals?

Her extensive regulatory background could potentially enhance Eton's chances of successfully navigating FDA processes for its products.